Abstract
Forty chronic schizophrenics, 27 men and 13 women, participated in a 6-month evaluation of pipothiazine palmitate (PP) and received monthly as injections a mean dose of 112 mg of this depot neuroleptic for long-term maintenance therapy with minimal side effects (mostly extrapyramidal), with excellent local and systemic tolerance and without obvious long-term toxicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
